Westminster, Colorado Clinical Trials

A listing of Westminster, Colorado clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 68 clinical trials
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

adjuvant chemotherapy
lung cancer
National Jewish Health-Northern Hematology Oncology
 (2.7 away) Contact site
  • 08 Aug, 2022
  • +1028 other locations
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (LIBRETTO-001)

This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

measurable disease
kidney function test
systemic therapy
renal function
ret inhibitor
Sarah Cannon Research Institute at HealthONE
 (8.0 away) Contact site
  • 10 Aug, 2022
  • +85 other locations
Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)

This is a phase 3, randomized, double-blind, active comparator-controlled study of the safety, tolerability, and immunogenicity of V116 compared to PCV20 (pneumococcal 20-valent conjugate vaccine ([Prevnar 20™ / APEXXNAR™]) in pneumococcal vaccine-naïve adults. It is hypothesized that V116 is noninferior to PCV20 for the common serotypes and superior to PCV20 …

conjugate vaccine
pneumococcal vaccine
Accepts healthy volunteers
Paradigm Clinical Research Centers, Inc ( Site 0027)
 (5.5 away) Contact site
  • 12 Aug, 2022
  • +47 other locations
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and nivolumab, followed by nivolumab with cabozantinib in patients with untreated renal cell carcinoma that has spread to other parts of the body. The addition of cabozantinib to the …

kidney cancer
programmed cell death 1 ligand 1
Kaiser Permanente-Franklin
 (6.7 away) Contact site
  • 12 Aug, 2022
  • +347 other locations
Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy

This is a 52-week, Phase 3 multi-center, randomized, double-blind and placebo-controlled study to assess the safety and clinical efficacy of two dosing regimens of ligelizumab (240 mg and 120 mg) subcutaneous injection every 4 weeks (SCq4w) in participants with a medically confirmed diagnosis of IgE-mediated peanut allergy.

Novartis Investigative Site
 (9.8 away) Contact site
  • 09 Aug, 2022
  • +46 other locations
Novel Experimental COVID-19 Therapies Affecting Host Response (NECTAR)

The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing progression to critical illness, multiorgan failure, or death. Our objective is to determine whether modulating the host tissue response …

Denver Health Medical Center
 (7.1 away) Contact site
  • 08 Aug, 2022
  • +30 other locations
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Solid Tumors Malignancies

This clinical trial is evaluating a drug called BT8009 alone and in combination with nivolumab in participants with advanced solid tumors associated with Nectin-4 expression or in participants with advanced solid tumor malignancies having renal insufficiency. The main goals of this study are to: Find the recommended dose of BT8009 …

triple negative breast cancer
targeted therapy
lung cancer
Sarah Cannon Research Institute at HealthONE
 (8.0 away) Contact site
  • 09 Aug, 2022
  • +18 other locations
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial enrolls participants for …

desmoid tumors
bronchoalveolar carcinoma
human immunodeficiency virus
National Jewish Health-Northern Hematology Oncology
 (2.7 away) Contact site
  • 10 Aug, 2022
  • +751 other locations
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic …

treatment regimen
serum pregnancy test
multiple myeloma
skin cancer
Rocky Mountain Cancer Centers-Thornton
 (2.7 away) Contact site
  • 08 Aug, 2022
  • +908 other locations
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

This phase II trial compares cabozantinib alone and the combination of cabozantinib and nivolumab to standard chemotherapy in the treatment of patients with non-squamous non-small cell lung cancer (NSCLC). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal …

cardiac disease
targeted therapy
National Jewish Health-Northern Hematology Oncology
 (2.7 away) Contact site
  • 08 Aug, 2022
  • +438 other locations